Eli Lilly: Q1 beats consensus

(CercleFinance.com) - Eli Lilly has reported adjusted (non-GAAP) net profit that is up 29% at 1.
6 billion dollars for the first three months of 2020, representing EPS of 1.75 dollar, nearly thirty cents above the consensus.

The Indianapolis based pharmaceutical laboratory's revenues increased by 15% to 5.86 billion dollars, with growth boosted by demand relating to the coronavirus pandemic. Note that products launched since 2014 represented 51% of its total revenues.

Eli Lilly said that it has adjusted its FY targets, expecting adjusted EPS of between 6.70 dollars and 6.90 dollars (against 6.70-6.80 dollars previously), for revenues that it still expects between 23.7 billion and 24.2 billion dollars.


Copyright (c) 2020 CercleFinance.com. All rights reserved.